These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 310362)

  • 41. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests.
    Mosley WH; Woodward WE; Aziz KM; Rahman AS; Chowdhury AK; Ahmed A; Feeley JC
    J Infect Dis; 1970 May; 121():Suppl 121:1-9. PubMed ID: 4912069
    [No Abstract]   [Full Text] [Related]  

  • 42. Further observations on the stability of cholera vaccine at different temperatures.
    Ahuja S; Gupta RK; Sharma SB; Maheshwari SC; Bhandari SK; Saxena SN
    Vaccine; 1987 Sep; 5(3):184-6. PubMed ID: 3673205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cholera vaccine field trials in east Pakistan. 1. Reaction and antigenicity studies.
    Benenson AS; Joseph PR; Oseasohn RO
    Bull World Health Organ; 1968; 38(3):347-57. PubMed ID: 5302328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Ferric ammonium citrate as virulence-enhancing agent in the toxicity test of Vibrio cholerae and the potency assay of cholera vaccine].
    Tsai MY; Lu CH
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 Feb; 22(1):75-81. PubMed ID: 2791724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Standardization of cholera vaccine and preparation of a national reference standard].
    Nenkov P; Manakhilov R; Polikar A; Karacholeva M; Genova Iu
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Aug; (8):55-8. PubMed ID: 6485669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stability of cholera and typhoid vaccines.
    Joó I; Zsidai J
    J Biol Stand; 1979; 7(4):341-8. PubMed ID: 536377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protective antigens from El Tor vibrios. 2. Responses in animals and man to a partially purified Ogawa lipopolysaccharide antigen.
    Watanabe Y; Verwey WF; Macdonald EM
    Bull World Health Organ; 1965; 32(6):823-31. PubMed ID: 5294307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The first British reference preparations of cholera vaccine (Inaba) and of cholera vaccine (Ogawa).
    Ford A; Seagroatt V
    J Biol Stand; 1977; 5(1):69-78. PubMed ID: 838751
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of HIV status and retinol on immunogenicity to oral cholera vaccine in adult population living in an endemic area of Lukanga Swamps, Zambia.
    Luchen CC; Mwaba J; Ng'ombe H; Alabi PIO; Simuyandi M; Chilyabanyama ON; Hatyoka LM; Mubanga C; Bosomprah S; Chilengi R; Chisenga CC
    PLoS One; 2021; 16(12):e0260552. PubMed ID: 34855835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chelometric determination of aluminium in vaccines.
    Meijerman GW; Van Lier KL
    Bull World Health Organ; 1965; 33(1):27-31. PubMed ID: 5294262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The production of a vaccine based on Craig's toxin.
    Thomson RO; Walker PD; Knight PA
    Prog Immunobiol Stand; 1971; 5():335-40. PubMed ID: 4660538
    [No Abstract]   [Full Text] [Related]  

  • 52. [Experimental research on a cholera vaccine of lysed vibrios by mouth].
    PUGNANI E
    G Batteriol Immunol; 1949 Nov; 41(5):315-7. PubMed ID: 15410111
    [No Abstract]   [Full Text] [Related]  

  • 53. The antigenicity of cholera vaccine prepared in fluid medium.
    RANTA LE; MCCREERY PM
    Can J Med Sci; 1953 Aug; 31(4):338-42. PubMed ID: 13082452
    [No Abstract]   [Full Text] [Related]  

  • 54. Preparation of cholera vaccines by fluorocarbon extraction of cholera Vibrio suspensions.
    Altieri PL; Berman S; Groffinger A; Lowenthal JP
    Infect Immun; 1970 Apr; 1(4):334-7. PubMed ID: 16557738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. STUDIES ON VACCINATION AGAINST CHOLERA. I. PREPARATION AND LABORATORY ASSAY OF CHOLERA VACCINES.
    JOO I; PUSZTAI Z; MATE J; RETHY L; ECKHARDT E; JUHASZ VP
    Z Immunitats Allergieforsch; 1964 Aug; 127():230-48. PubMed ID: 14310745
    [No Abstract]   [Full Text] [Related]  

  • 56. [Impressions of a World Health Organization course on cholera bacteriology and the most recent views on cholera vaccine; 2-11 October 1965 at Teheran].
    Tulga T
    Turk Hij Tecr Biyol Derg (1961); 1965; 25(2):206-25. PubMed ID: 5882600
    [No Abstract]   [Full Text] [Related]  

  • 57. Structural characterization of a protein adsorbed on aluminum hydroxide adjuvant in vaccine formulation.
    Cerofolini L; Giuntini S; Ravera E; Luchinat C; Berti F; Fragai M
    NPJ Vaccines; 2019; 4():20. PubMed ID: 31149351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved quantification of protein in vaccines containing aluminum hydroxide by simple modification of the Lowry method.
    Lee N; Shin S; Chung HJ; Kim DK; Lim JM; Park H; Oh HJ
    Vaccine; 2015 Sep; 33(39):5031-4. PubMed ID: 26275477
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toward an effective prophylactic immunity to cholera.
    Burrows W
    J Infect Dis; 1970 May; 121():Suppl 121:58+. PubMed ID: 5421430
    [No Abstract]   [Full Text] [Related]  

  • 60. [PROTECTIVE ACTIVITY OF ALUMINUM HYDROXIDE ON THE ANTIGENIC POWER OF THE SALK TYPE OF ANTIPOLIOMYELITIS VACCINE].
    HAHN E; BONANI V; GIACOMETTI G
    Boll Ist Sieroter Milan; 1963; 42():369-71. PubMed ID: 14101985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.